Maravai LifeSciences Holdings Inc MRVI.OQ MRVI.O is expected to show a fall in quarterly revenue when it reports results on November 6 for the period ending September 30 2025
The San Diego California-based company is expected to report a 24.8% decrease in revenue to $49.003 million from $65.2 million a year ago, according to the mean estimate from 11 analysts, based on LSEG data.
LSEG's mean analyst estimate for Maravai LifeSciences Holdings Inc is for a loss of 8 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Maravai LifeSciences Holdings Inc is $4.50, about 34.7% above its last closing price of $2.94
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.07 | -0.07 | -0.08 | Missed | -12.8 |
Mar. 31 2025 | -0.07 | -0.07 | -0.08 | Missed | -12 |
Dec. 31 2024 | -0.04 | -0.04 | -0.06 | Missed | -50 |
Sep. 30 2024 | -0.01 | -0.01 | -0.02 | Missed | -160.1 |
Jun. 30 2024 | 0.00 | 0.00 | 0.00 | Met | -100 |
Mar. 31 2024 | -0.03 | -0.03 | -0.02 | Beat | 21.4 |
Dec. 31 2023 | -0.01 | -0.01 | 0.01 | Beat | 184.6 |
Sep. 30 2023 | 0.00 | 0.01 | -0.01 | Missed | -257.2 |
This summary was machine generated November 4 at 22:49 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments